RefleXion Medical, a Burlingame, CA-based medical device company developing a biologically-guided radiation therapy system for cancer treatment, raised an $11.6m Series A funding round.
The round was led by Sofinnova Partners with participation from Pfizer Venture Investments and Venrock. In conjunction with the funding, Antoine Papiernik from Sofinnova Partners, Bill Burkoth from Pfizer Venture and Colin Cahill from Venrock joined RefleXion’s board.
The company intends to use the funds to expand its R&D organization and accelerate the system’s development.
Led by Dr. Samuel Mazin, President, RefleXion Medical has developed technology that integrates positron emission tomography (PET) with radiation therapy to allow tumors to continuously signal their location during treatment. It provides the potential to deliver a higher dose of therapeutic radiation to multiple cancerous lesions and spare surrounding healthy tissue.
Early validation of the platform was funded by the National Cancer Institute at the National Institutes of Health, part of the U.S. Department of Health and Human Services (1R43CA153466-1A1). and inventor of the company’s core technology.